Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Post-Novartis, GSK Assures Immuno-Oncology R&D Running At Full Speed

This article was originally published in The Pink Sheet Daily

Executive Summary

Working with partners, GSK aims to have at least two new cancer immunotherapies in the clinic by mid-2015, says Axel Hoos, the former BMS exec who developed the checkpoint grandfather Yervoy.

You may also be interested in...



GSK's Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion

Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10 years.

Emerging Markets Earnings Roundup: GSK (Part 9)

GlaxoSmithKline executives spoke to the point about continued sales issues in China, but offered some guidance that its issues with a compliance scandal that started in July last year are stabilizing. CEO Andrew Witty spent much of his time talking about the massive deal with Novartis, leaving Simon Dingemans, chief financial officer, to fill in details on emerging markets.

Emerging Markets Earnings Roundup: GSK (Part 9)

GlaxoSmithKline executives spoke to the point about continued sales issues in China, but offered some guidance that its issues with a compliance scandal that started in July last year are stabilizing. CEO Andrew Witty spent much of his time talking about the massive deal with Novartis, leaving Simon Dingemans, chief financial officer, to fill in details on emerging markets.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077229

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel